Sunpharma Ppt Final 18092015
-
Upload
pratheesh-tulsi -
Category
Documents
-
view
7 -
download
0
Transcript of Sunpharma Ppt Final 18092015
![Page 1: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/1.jpg)
FINANCIAL STATEMENT ANALYSIS OF SUNPHARMA INDUSTRIES
Presented By:PadmarajPratheeshGouravPrakashAbhishek
![Page 2: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/2.jpg)
INTRODUCTION
• No. 1 Pharma Company in India & Ranked 5th in the US (Market Size)
• Largest Indian Pharma Company in Emerging Markets• Presence in more than 150 countries across Branded and
Generic markets• Segment - Specialty products, branded generics, complex
generics, pure generics & APIs
![Page 3: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/3.jpg)
![Page 4: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/4.jpg)
FY11 FY12 FY13 FY14 FY1568%
70%
72%
74%
76%
78%
80%
82%
84%
74%
80%
82%83%
75%
Gross Margin
FY11 FY12 FY13 FY14 FY150%
5%
10%
15%
20%
25%
30%
35%
40%
32% 32% 32%
35%
17%
Net Margin
Profitability Ratios
![Page 5: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/5.jpg)
Profitability RatiosRatio 2013 2014 2015 Industry Average
ROE 24% 31% 19% 25%
Net Margin 32% 35% 18% 14%
2013 2014 20150%
5%
10%
15%
20%
25%
30%
35%
ROE
ROE
![Page 6: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/6.jpg)
Dupont Analysis
Return on Equity
Operating Efficiency
Asset use Efficiency
Financial Leverage
![Page 7: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/7.jpg)
Dupont Analysis
Return on Equity
Operating Efficiency
Asset use Efficiency
Financial Leverage
![Page 8: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/8.jpg)
Ratio 2013 2014 2015 Industry Average
ROE 24% 31% 19% 25%
Net Margin 32% 35% 18% 14%
2013 2014 20150%
5%
10%
15%
20%
25%
30%
35%
Net Margin
Net Margin
Operating Efficiency
![Page 9: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/9.jpg)
Dupont AnalysisReturn on Equity
Operating Efficiency Asset use Efficiency Financial Leverage
![Page 10: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/10.jpg)
Dupont Analysis
Return on Equity
Operating Efficiency
Asset use Efficiency
Financial Leverage
![Page 11: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/11.jpg)
Asset Efficiency RatioRatio 2013 2014 2015 Industry Average
Assets Turnover
0.56 0.64 0.69 1.29
Fixed Assets Turnover
2.21 2.75 2.48 2.33
2013 2014 20150.53
0.5350.54
0.5450.55
0.5550.56
0.565
Assets Turnover Ratio
Assets Turnover Ratio
![Page 12: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/12.jpg)
Ratio 2013 2014 2015 Industry Average
Assets Turnover
0.54 0.64 0.69 1.29
Fixed Assets Turnover
2.21 2.75 2.48 2.33
2013 2014 20150
0.51
1.52
2.53
Fixed Assets Turnover Ratio
Fixed Assets Turnover Ratio
Asset Efficiency Ratio
![Page 13: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/13.jpg)
Assets
Fixed Assets Current Assets
![Page 14: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/14.jpg)
Assets
Fixed Assets Current Assets
![Page 15: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/15.jpg)
Assets
Fixed AssetsCurrent Assets
Fixed Asset efficiency seems to be fine but not the Current Assets Efficiency
![Page 16: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/16.jpg)
Liquidity Ratios2013 2014 2015 Industry Average
Current Ratio
2.6 3.4 2.3 1.4
Quick Ratio
3.4 2.6 1.7 1.3
2013 2014 20150
1
2
3
4
Chart Title
Current Ratio
![Page 17: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/17.jpg)
Liquidity Ratios2013 2014 2015 Industry Average
Current Ratio
2.6 3.4 2.3 1.4
Quick Ratio
3.4 2.6 1.7 1.3
2013 2014 20150
1
2
3
4
Quick Ratio
Quick Ratio
![Page 18: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/18.jpg)
Ratio 2013 2014 2015 Industry Average
Inventory Turnover
4.36 5.12 4.81 4.64
Receivables Turnover
4.66 7.27 5.14 5.11
Collection Period 78 50 71 -Payables Turnover
10.62 12.04 8.65 -
2013 2014 20153.8
4.2
4.6
5
Inventory Turnover Ratio
Inventory Turnover Ra-tio
Efficiency Ratios
![Page 19: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/19.jpg)
2013 2014 20150
2
4
6
8
Receivables Turnover
Inventory Receivables Ratio
Ratio 2013 2014 2015 Industry Average
Inventory Turnover
4.36 5.12 4.81 4.64
Receivables Turnover
4.66 7.27 5.14 5.11
Collection Period 78 50 71 -Payables Turnover
10.62 12.04 8.65 -
Efficiency Ratios
![Page 20: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/20.jpg)
2013 2014 20150
20406080
100
Collection Period
Collection Period
Efficiency RatiosRatio 2013 2014 2015 Industry Average
Inventory Turnover
4.36 5.12 4.81 4.64
Receivables Turnover
4.66 7.27 5.14 5.11
Collection Period 78 50 71 -Payables Turnover
10.62 12.04 8.65 -
![Page 21: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/21.jpg)
2013 2014 20150
4
8
12
Payables Turnover Ratio
Payables Turnover Ra-tio
Efficiency RatiosRatio 2013 2014 2015 Industry Average
Inventory Turnover
4.36 5.12 4.81 4.64
Receivables Turnover
4.66 7.27 5.14 5.11
Collection Period 78 50 71 -Payables Turnover
10.62 12.04 8.65 -
![Page 22: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/22.jpg)
DuPont Analysis
Return on Equity
Operating Efficiency
Asset use Efficiency
Financial Leverage
![Page 23: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/23.jpg)
DuPont Analysis
Return on Equity
Operating Efficiency
Asset use Efficiency
Financial Leverage
![Page 24: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/24.jpg)
Debt Coverage RatiosRatio 2013 2014 2015 Industry Average
Debt/Equity 1.3% 13% 30% 38%
Interest Cover 110.8 161.3 13.5 84.94
2013 2014 20150.00%5.00%
10.00%15.00%20.00%25.00%30.00%35.00%
Debt/Equity Ratio
Debt/Equity Ratio
![Page 25: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/25.jpg)
Ratio 2013 2014 2015 Industry Average
Debt/Equity 1.3% 13% 30% 38%
Interest Cover 110.8 161.3 13.5 84.94
2013 2014 20150
20406080
100120140160180
Interest Cover Ratio
Interest Cover Ratio
Debt Coverage Ratios
![Page 26: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/26.jpg)
Diagnosis
Poor Management of Current Assets
High debt and Interest costs
Solutions
Reducing the Operating Cycle, (Payback period,
Payable turnover), Collection period)
Reducing Interest costs and Debt
Reasons
Integration costs and Costs incurred on
Ranbaxy
Increase in borrowing (Ranbaxy debts taken
on books)
Increase in R&D expenditure
![Page 27: Sunpharma Ppt Final 18092015](https://reader033.fdocuments.us/reader033/viewer/2022052701/563db986550346aa9a9e244d/html5/thumbnails/27.jpg)